Biolase Net Income 2010-2024 | BIOL

Biolase net income from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Biolase Annual Net Income
(Millions of US $)
2023 $-38
2022 $-29
2021 $-17
2020 $-34
2019 $-18
2018 $-22
2017 $-21
2016 $-18
2015 $-20
2014 $-19
2013 $-11
2012 $-3
2011 $-4
2010 $-12
2009 $-3
Biolase Quarterly Net Income
(Millions of US $)
2024-06-30 $-3
2024-03-31 $-6
2023-12-31 $-22
2023-09-30 $-5
2023-06-30 $-5
2023-03-31 $-6
2022-12-31 $-10
2022-09-30 $-8
2022-06-30 $-6
2022-03-31 $-5
2021-12-31 $-5
2021-09-30 $-3
2021-06-30 $-1
2021-03-31 $-7
2020-12-31 $-6
2020-09-30 $-17
2020-06-30 $-5
2020-03-31 $-6
2019-12-31 $-4
2019-09-30 $-5
2019-06-30 $-4
2019-03-31 $-5
2018-12-31 $-7
2018-09-30 $-5
2018-06-30 $-5
2018-03-31 $-5
2017-12-31 $-8
2017-09-30 $-5
2017-06-30 $-4
2017-03-31 $-4
2016-12-31 $-7
2016-09-30 $-3
2016-06-30 $-4
2016-03-31 $-4
2015-12-31 $-2
2015-09-30 $-5
2015-06-30 $-7
2015-03-31 $-5
2014-12-31 $-4
2014-09-30 $-3
2014-06-30 $-6
2014-03-31 $-5
2013-12-31 $-2
2013-09-30 $-4
2013-06-30 $-3
2013-03-31 $-3
2012-12-31 $1
2012-09-30 $-1
2012-06-30 $-2
2012-03-31 $-2
2011-12-31 $-2
2011-09-30 $-1
2011-06-30 $-1
2011-03-31 $-1
2010-12-31 $0
2010-09-30 $-3
2010-06-30 $-4
2010-03-31 $-5
2009-12-31 $-1
2009-09-30 $1
2009-06-30 $2
2009-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.002B $0.049B
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $72.759B 20.02
Becton Dickinson (BDX) United States $70.067B 18.98
Cardinal Health (CAH) United States $27.486B 15.09
West Pharmaceutical Services (WST) United States $22.751B 44.36
Cooper (COO) United States $21.053B 29.97
Labcorp (LH) United States $19.302B 16.08
Align Technology (ALGN) United States $17.720B 34.23
Henry Schein (HSIC) United States $8.939B 16.37
Merit Medical Systems (MMSI) United States $5.628B 29.75
DENTSPLY SIRONA (XRAY) United States $5.127B 13.74
CONMED (CNMD) United States $2.257B 19.63
Patterson (PDCO) United States $1.982B 10.46
STAAR Surgical (STAA) United States $1.628B 73.53
Lifevantage (LFVN) United States $0.099B 13.72
Pro-Dex (PDEX) United States $0.080B 40.22